Kemudin I.V.

Ceftriaxone, the active ingredient in Kemudin I.V., is a third‑generation cephalosporin presented as an injection solution for intravenous use. It treats a broad range of serious bacterial infections, including pneumonia, meningitis, gonorrhea, urinary tract infections, and skin‑soft‑tissue infections in adults and children.

GNH USA supplies Kemudin I.V. as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals worldwide. The company provides regulated, quality‑assured products to healthcare facilities across multiple continents.

Ceftriaxone is a broad‑spectrum antibacterial that targets Gram‑negative and Gram‑positive organisms in several infection categories. - Community‑acquired pneumonia: effective bacterial eradication leading to clinical recovery. - Bacterial meningitis: rapid bactericidal activity reduces mortality and neurological complications. - Gonorrhea: single‑dose therapy eliminates Neisseria gonorrhoeae infection. - Urinary tract infections: resolves complicated UTIs caused by susceptible organisms. - Skin and soft‑tissue infections: clears cellulitis and wound infections caused by susceptible bacteria.

Ceftriaxone may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Injection site pain: mild discomfort at the infusion site. - Diarrhea: loose stools, often self‑limited. - Nausea: occasional feeling of queasiness. - Rash: mild skin erythema. - Elevated liver enzymes: transient increase in ALT/AST. - Headache: mild to moderate.

Serious or Rare Side Effects: - Anaphylaxis: severe allergic reaction with respiratory distress. - Stevens‑Johnson syndrome: rare severe skin and mucosal detachment. - Clostridioides difficile‑associated diarrhea: severe colitis. - Hemolytic anemia: immune‑mediated red cell destruction. - Severe hepatic dysfunction: jaundice, elevated bilirubin. - Pseudomembranous colitis: inflammation of colon.

Before using Ceftriaxone, clinicians should consider several safety precautions to minimize risk. - Renal impairment: adjust dosing and monitor renal function. - Hepatic impairment: use with caution; monitor liver enzymes. - Neonates and infants <28 days: risk of bilirubin displacement; avoid high doses. - Known allergy to β‑lactams: contraindicated due to risk of severe hypersensitivity. - Pregnancy and lactation: safety category unknown; weigh benefits against potential risks. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Ceftriaxone interacts with several drugs, requiring attention to avoid reduced efficacy or increased toxicity.

Major Interactions (Avoid): - Calcium‑containing IV solutions: precipitation can occur; avoid simultaneous administration. - Warfarin: enhanced anticoagulant effect may increase bleeding risk. - Aminoglycosides: combined nephrotoxicity; monitor renal function closely.

Moderate Interactions (Monitor Closely): - NSAIDs: may increase risk of renal impairment. - Oral contraceptives: possible reduction in contraceptive effectiveness. - Diuretics: may affect electrolyte balance and renal clearance. - Probenecid: can increase ceftriaxone plasma levels, adjust dose if needed.